On December 16, Array BioPharma announced its new cancer drug, binimetinib, showed success in stage 3 clinical trials.
According to the drug company, binimetinib may be used to treat people with advanced NRAS-mutant melanoma, a particularly deadly form of skin cancer. The trial showed that the drug extended the time it takes for cancer to grow and spread.
In the randomized 402-person trial, those receiving binimetinib had a progression-free survival rate of 2.8 months versus 1.5 months for those in the trial who took the currently used dacarbazine treatment.